RT Journal Article
SR Electronic
T1 Acquired decrease of the C3b/C4b receptor (CR1, CD35) and increased C4d deposits on Erythrocytes from ICU COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.10.20162412
DO 10.1101/2020.08.10.20162412
A1 Kisserli, Aymric
A1 Schneider, Nathalie
A1 Audonnet, Sandra
A1 Tabary, Thierry
A1 Goury, Antoine
A1 Cousson, Joel
A1 Mahmoudi, Rachid
A1 Bani-Sadr, Firouze
A1 Kanagaratnam, Lukshe
A1 Jolly, Damien
A1 Cohen, Jacques HM
YR 2020
UL http://medrxiv.org/content/early/2020/12/02/2020.08.10.20162412.abstract
AB In order to study the mechanisms of COVID-19 damage following the complement activation phase occurring during the innate immune response to SARS-CoV-2, the CR1, receptor regulating complement activation factor, CR1 (CD35, the C3b/C4b receptor), C4d deposits on Erythrocytes (E), and the products of complement activation C3b/C3bi were assessed in 52 COVID-19 patients undergoing O2 therapy or assisted ventilation in ICU units in Rheims France.An acquired decrease of CR1 density of E from COVID-19 patients was observed (Mean 418, SD 162, N=52) versus healthy individuals (Mean = 592, SD = 287, N= 400), Student’s t-test p<10−6, particularly among fatal cases, and paralleling several clinical severity parameters.Large deposits of C4d on E in patients were well above values observed in normal individuals, mostly without concomitant C3 deposits, in more than 80% of the patients. This finding is reminiscent of the increased C4d deposits on E previously observed to correlate with sub endothelial pericapillary deposits in organ transplant rejection, and with clinical SLE flares. Conversely, significant C3 deposits on E were only observed among ¼ of the patients.The decrease of CR1/E density, deposits of C4 fragments on E and previously reported detection of virus spikes or C3 on E among COVID-19 patients, suggest that the handling and clearance of immune complex or complement fragment coated cell debris may play an important role in the pathophysiology of SARS-CoV-2. Measurement of C4d deposits on E might represent a surrogate marker for assessing inflammation and complement activation occurring in organ capillaries and CR1/E decrease might represent a cumulative index of complement activation in COVID-19 patients.Taken together, these original findings highlight the participation of complement regulatory proteins and indicate that E are important in immune pathophysiology of COVID-19 patients. Besides a potential role for monitoring the course of disease, these observations suggest that novel therapies such as the use of CR1, or CR1-like molecules with the aim of down regulating complement activation and inflammation for therapy should be considered.HIGHLIGHTSAcquired decrease of CR1 density on E in COVID-19 patients correlated with clinical severity and mortality.Large C4d deposits were found on E in most patients, reminiscent of those observed on E of patients undergoing organ transplant rejection that were associated with peri-capillary deposits, as well as on E from patients undergoing SLE flares.C4d deposits on E may be useful as a surrogate marker for inflammation and complement activation in organ capillaries.Decreased CR1/E may be useful as a cumulative index of complement activation in COVID-19 patients.The use of CR1 or CR1-like molecules for down-regulating complement activation for therapy should also be considered.These original findings indicate the participation of complement regulatory proteins in COVID-19 and on the role of E in immune mechanisms of the disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPartial Funding by the Not-for-profit Organisation "Association pour le Developement de l'Immunologie et de la Microbiologie Remoise" ADMIR Grant 2020/0001.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Rheims University Hospital has obtained the authorization to create plasma and serum libraries from the Human Protection Committee (CPP Est III, national number: 2020-A01093-36) in order to study the soluble Vascular Endothelial Growth Factor (sFlt-1) receptor in intensive care patients with severe COVID-19 pneumonitis. The patients or their families signed an informed consent form to participate, specifying that other elements, such as the red blood cells, that were to be discarded, could be used for research for other purposes, in the context of the COVID-19 epidemic. Blood donors were healthy volunteers who signed the general informed consent from the national Etablissement Francais du Sang (EFS). Aged patients were from a cohort with individual informed consents approved by the regional ethics committee (CPP Est II), under the protocol number 2011-A00594-37. Consents of the healthy volunteers of the C4d/E reference cohort were also approved by the local ethics committee in 2006.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe can provide upon request from researchers fresh reference E without charge for the calibration curve of Flow Cytometry measurement of CR1/E. As well as assistance for setting-up methologies used from the corresponding Author.CR1complement receptor type 1CR1/Ecomplement receptor type 1 per erythrocyteCR1/E%complement receptor type 1 per erythrocyte as percentage of the CR1/E density expected from the CR1 density polymorphism genotype of the patientC3complement fragment 3C4complement fragment 4C1qcomplement component 1qC1rcomplement component 1rC1scomplement component 1sC3acomplement component 3aC3bcomplement component 3bC4acomplement component 4aC4dcomplement component 4dC5acomplement component 5aDATdirect antiglobulin testEerythrocytesFITCfluorescein iso-thio-cyanateHbA1cglycosylated hemoglobin type AICUintensive care unitMBLmannan binding lectinMASP1mannan binding lectin serine protease1 PE phyco-erythrinSa02oxygen saturationSLEsystemic lupus erythematosus